{"id":"W4308056077","doi":"10.1182/bloodadvances.2022007611","title":"Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research; Pharmacyclics; Genentech; Syndax Pharmaceuticals; National Institutes of Health; Incyte; Therakos; Florida Department of Health; Gilead Sciences; Amgen; National Heart, Lung, and Blood Institute; Pfizer; National Institute of Allergy and Infectious Diseases; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Disease; Medicine; Intensive care medicine; Hematopoietic stem cell transplantation; Consensus conference; Graft-versus-host disease; Perspective (graphical); Stem cell; Immunology; Bioinformatics; Pathology; Biology; Internal medicine; Computer science","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03558945,0.001459798,0.002096614,0.002778138,0.002371051,0.006742719,0.004432982,0.009796806,0.008542331],"category_scores_gemma":[0.02981188,0.0005510434,0.001935917,0.003019145,0.002398925,0.004109439,0.006145602,0.01871466,0.004557405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005505351,"about_ca_system_score_gemma":0.05135812,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006160844,"about_ca_topic_score_gemma":0.01311624,"domain_scores_codex":[0.9878078,0.004211526,0.002009661,0.0006327714,0.004102803,0.001235461],"domain_scores_gemma":[0.9531583,0.0100258,0.003737822,0.001287978,0.02038701,0.01140311],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007859206,0.0001373716,0.0008644958,0.001818861,0.00006996465,0.0001354358,0.0001603968,0.0004486656,0.0004181348,0.009971299,0.7648583,0.2210386],"study_design_scores_gemma":[0.00008090428,0.0001157099,0.001163682,0.005423671,0.000105949,0.0002489564,0.0003013326,0.0002834952,0.0003389357,0.01053221,0.9813603,0.00004484176],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.0009877592,0.1347097,0.00547063,0.7974674,0.04454581,0.0004198797,0.0009853535,0.0002377784,0.01517566],"genre_scores_gemma":[0.01678282,0.4355932,0.06084836,0.3863488,0.06720264,0.001805019,0.006004599,0.0004647202,0.02494974],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.03558945,"threshold_uncertainty_score":0.1882172,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01962665067547011,"score_gpt":0.3082489974875755,"score_spread":0.2886223468121054,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}